Steroid therapy and olfactory training are common treatments for olfactory loss. Systemic steroid treatment is the most effective approach for treating sinonasal olfactory loss. Olfactory training is typically effective for treating sensorineural olfactory loss. However, the differences in mechanisms of steroid therapy and olfactory training for olfactory dysfunction are unclear. The aim of this study was thus to evaluate the differences in mechanisms of olfactory training and steroid therapy.
Subjects and Methods
Mice in each group were administered 3-methylindole at a dose of 300 mg/kg. Olfactory function was evaluated with a food-finding test once a week. The olfactory neuroepithelium was harvested for histologic examination and protein analysis. Subsequently, data analysis, gene ontology and pathway analysis, quantitative real-time polymerase chain reaction of mRNA, and western blot analysis were conducted.
Results
Mice were divided into four groups according to treatment. Control, anosmia, training, and steroid groups resumed food-finding. MMP27, CCL22 and IL18rap mRNA expression were significantly increased in the training group compared to that in the steroid group. IL1R2 mRNA expression was significantly higher in the olfactory neuroepithelium of steroid-treated mice than in that of the training group mice.
Conclusions
Steroid therapy improved olfactory function via anti-inflammatory effects, unlike olfactory training which involved cell regeneration and tissue remodeling. Protein and gene analyses revealed that steroid therapy and olfactory training are underpinned by distinct mechanisms. Selection of the most appropriate treatment will be dependent on the cause of olfactory loss.
DammMPikartLKReimannH, et al.
Olfactory training is helpful in postinfectious olfactory loss: a randomized controlled multicenter study. Laryngoscope. 2014;
124(4): 826–831.
2.
HolbrookEHLeopoldDA.An updated review of clinical olfaction. Curr Opin Otolaryngol Head Neck Surg. 2006;
14(1):23–28.
3.
KadohisaM.Effects of odor on emotion, with implications. Front Syst Neurosci. 2013;
7:66.
4.
HummelTWhitcroftKLAndrewsP, et al.
Position paper on olfactory dysfunction. Rhinol Suppl. 2017;
54(26):1–30.
5.
RobinsonAMKernRCFosterJDFong KJ, Pitovski DZ.
Expression of glucocorticoid receptor mRNA and protein in the olfactory mucosa: physiologic and pathophysiologic implications. Laryngoscope. 1998;
108(8 Pt 1):1238–1242.
6.
RobinsonAMKernRCFosterJDKrozowski ZS, Pitovski DZ.
Mineralocorticoid receptors in the mammalian olfactory mucosa. Ann Otol Rhinol Laryngol. 1999;
108(10):974–981.
7.
SchrieverVAMerkonidisCGuptaNHummel C, Hummel T.
Treatment of smell loss with systemic methylprednisolone. Rhinology. 2012;
50(3):284–289.
8.
FongKJKernRCFosterJDZhao JC, Pitovski DZ.
Olfactory secretion and sodium, potassium-adenosine triphosphatase: regulation by corticosteroids. Laryngoscope. 1999;
109(3):383–388.
9.
CainWSStevensJCNickouCMGiles A, Johnston I, Garcia-Medina MR.
Life-span development of odor identification, learning, and olfactory sensitivity. Perception. 1995;
24(12):1457–1472.
10.
EngenTBosackTN.Facilitation in olfactory detection. J Comp Physiol Psychol. 1969;
68(3):320–326.
11.
LivermoreALaingDG.Influence of training and experience on the perception of multicomponentodor mixtures. J Exp Psychol Hum Percept Perform. 1996;
22(2):267–277.
12.
KimBGKimBYShinJHKim SW, Kim SW.
The effect of olfactory training using Korean version odorants: a preliminary study. Korean J Otorhinolaryngol-Head Neck Surg. 2018;
61(10):522–527.
13.
PekalaKChandraRKTurnerJH.Efficacy of olfactory training in patients with olfactory loss: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2016;
6(3):299–307.
14.
WilsonDABestARSullivanRM.Plasticity in the olfactory system: lessons for the neurobiology of memory. Neuroscientist. 2004;
10(6):513–524.
15.
MainlandJDBremnerEAYoungN, et al.
Olfactory plasticity: one nostril knows what the other learns. Nature. 2002;
419(6909):802.
16.
QinWXuanYLiuYJiang T, Yu C.
Functional connectivity density in congenitally and late blind subjects. Cereb Cortex. 2015;
25(9):2507–2516.
17.
KimBYParkJYKimEJKim BG, Kim SW, Kim SW.
The neuroplastic effect of olfactory training to the recovery of olfactory system in mouse model. Int Forum Allergy Rhinol. 2019;
9(7):715–723.
18.
KimJWHongSLLeeCHJeon EH, Choi AR.
Relationship between olfactory function and olfactory neuronal population in C57BL6 mice injected intraperitoneally with 3-methylindole. Otolaryngol Head Neck Surg. 2010;
143(6):837–842.
19.
ChoHJLeeYHKimBR, et al.
Newly developed method for mouse olfactory behavior tests using an automatic video tracking system. Auris Nasus Larynx. 2018;
45(1):103–110.
20.
WiethoffAJHarkemaJRKoretskyAP Brown WE.
Identification of mucosal injury in the murine nasal airways by magnetic resonance imaging: site-specific lesions induced by 3-methylindole. Toxicol Appl Pharmacol. 2001;
175(1):68–75.
21.
HongSCYooYSKimES, et al.
Development of KVSS test (Korean version of Sniffin’ sticks test). Korean J Otolaryngol Head Neck Surg. 1999;
42:855–860.
22.
KimBYParkJKimE, et al.
Olfactory ensheathing cells mediate neuroplastic mechanisms after olfactory training in mouse model. Am J Rhinol Allergy. 2020;34(2):217–229.
23.
MurphyCSchubertCRCruickshanksKJKlein BE, Klein R, Nondahl DM.
Prevalence of olfactory impairment in older adults. JAMA. 2002;
288(18):2307–2312.
24.
DammMTemmelAWelge-LussenA, et al.
Olfactory dysfunctions. Epidemiology and therapy in Germany, Austria and Switzerland. HNO. 2004;
52(2):112–120.
25.
NordinSMonschAUMurphyC.Unawareness of smell loss in normal aging and Alzheimer’s disease: discrepancy between self-reported and diagnosed smell sensitivity. J Gerontol B Psychol Sci Soc Sci. 1995;
50(4):P187–P192.
26.
SeidenAM.Postviral olfactory loss. Otolaryngol Clin North Am. 2004;
37(6):1159–1166.
27.
HeilmannSHuettenbrinkK-BHummelT. Local and systemic administration of corticosteroids in the treatment of olfactory loss. Am J Rhinol. 2004;
18(1):29–33.
28.
StennerMVentJHüttenbrinkKB.Topical therapy in anosmia: relevance of steroid-responsiveness. Laryngoscope. 2008;
118:1681–1686.
29.
StuckBAHummelT.Olfaction in allergic rhinitis: a systematic review. J Allergy Clin Immunol. 2015;
136(6):1460–1470.
30.
JiangRSWuSHLiangKLShiao JY, Hsin CH, Su MC.
Steroid treatment of posttraumatic anosmia. Eur Arch Otorhinolaryngol. 2010;
267(10):1563–1567.
31.
CzockDKellerFRascheFMHaussler U.
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;
44(1):61–98.
SpickettG.Urticaria and angioedema.J R Coll Physicians Edinb. 2014;
44(1):50–54.
34.
LambrouGIVlahopoulosSPapathanasiouC, et al.
Prednisolone exerts late mitogenic and biphasic effects on resistant acute lymphoblastic leukemia cells: relation to early gene expression. Leuk Res. 2009;
33(12):1684–1695.
35.
Gera K, Gupta N, Ahuja A, Shah A. Acute Alveolar Sarcoidosis Presenting With Hypoxaemic Respiratory Failure. BMJ Case Rep. 2014;bcr2013202247.
TianJPintoJMXinY, et al.
Dexamethasone affects mouse olfactory mucosa gene expression and attenuates genes related to neurite outgrowth. Int Forum Allergy Rhinol. 2015;
5(10):907–918.
41.
KonstantinidisITsakiropoulouEConstantinidisJ.Long term effects of olfactory training in patients with post-infectious olfactory loss. Rhinology. 2016;
54(2):170–175.
42.
HummelTRissomKRedenKRJHähner A, Weidenbecher M, Hüttenbrink KB.
Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009;
119(3):496–499.
43.
HaehnerAToschCWolzM, et al.
Olfactory training in patients with Parkinson’s disease. PLoS One. 2013;
8(4):e61680–e61687.
44.
YoungentobSLKentPF.Enhancement of odorant induced mucosal activity patterns in rats trained on an odorant. Brain Res. 1995;
670(1):82–88.
45.
KollndorferKKowalczykKHocheE, et al.
Recovery of olfactory function induces neuroplasticity effects in patients. Neural Plast. 2014;
2014:140419.
46.
Snoek-van BeurdenPAVon den HoffJW.Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. BioTechniques. 2005;
38(1):73–83.
47.
GodiskaRChantryDRaportCJ, et al.
Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med. 1997;
185(9):1595–1604.
48.
NomiyamaHImaiTKusudaJMiura R, Callen DF, Yoshie O.
Human chemokines fractalkine (SCYD1), MDC (SCYA22) and TARC (SCYA17) are clustered on chromosome 16q13. Cytogenet Cell Genet. 1998;
81(1):10–11.
49.
VulcanoMAlbanesiCStoppacciaroA, et al.
Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol. 2001;
31(3):812–822.
50.
SamsonMSoularuePVassartGParmentier M.
The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3. Genomics. 1996;
36(3):522–526.
51.
BornTLThomassenEBirdTASims JE.
Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem. 1998;
273(45):29445–29450.
52.
HaydenMSWestAPGhoshS.NF-κB and the immune response. Oncogene. 2006;
25(51):6758–6780.
53.
LiQVermaIM.NF-κB regulation in the immune system. Nat Rev Immunol. 2002;
2(10):725–734.
54.
LangDKnopJWescheH, et al.
The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol. 1998;
161(12):6871–6877.
55.
WangDZhangSLiLLiu X, Mei K, Wang X.
Structural insights into the assembly and activation of IL-1β with its receptors. Nat Immunol. 2010;
11(10):905–911. Oct
